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Summary
Pharmacokinetic studies are commonly performed using the two-stage approach.
The first stage involves estimation of pharmacokinetic parameters like the area under
the concentration versus time curve (AUC) for each analysis subject separately and
the second stage uses the individual parameter estimates for statistical inference.
This two-stage approach is not applicable in sparse sampling situations where only
one sample is available per analysis subject like in non-clinical in-vivo studies. In
a serial sampling design only one sample is taken from each analysis subject. A
simulation study was carried out to assess coverage, power and type I error of seven
methods to construct two-sided 90% confidence intervals for ratios of two AUC’s
assessed in a serial sampling design, which can be used to assess bioequivalence in
this parameter.
Keywords: AUC; bioequivalence; bootstrap; serial sampling design; serial sac-
rifice design; sparse sampling
1 Introduction
A formula to calculate a 1−α confidence interval for the area under the concentration
versus time curve (AUC) from 0 to the last observed time point assessed in a serial
sampling design for normally distributed errors based on the linear trapezoidal rule
is presented in [1]. Procedures based on the t-distribution are presented in [2] and in
[3]. A simulation study for these approaches can be found in [4]. Wolfsegger & Jaki
in [5] derive an estimator and a confidence interval for the AUC from 0 to infinity
(AUC0−∞) for a serial sampling design.
Heinzl [6] presented a test for the null hypothesis of no difference between two
AUC’s from 0 to the last time point using the critical value from a t-distribution
while Bailer & Ruberg [7] propose a permutation test for this null hypothesis using
a z-statistic as the test statistic to be resampled.
1
In this note we will consider the ratio of two AUC’s and the corresponding confi-
dence intervals which are often assessed in bioequivalence studies using the confidence
interval inclusion approach. One of the main advantages of considering ratios instead
of the differences is interpretability. While the same conclusions can be obtained from
both approaches it is often easier to discuss ratios. The problem of bioequivalency is
discussed in great detail in the FDA guideline ‘Statistical Approaches to Establishing
Bioequivalence’ [8]. The guideline also addresses in-vitro and in-vivo studies for in-
vestigational new drug applications in which sparse sampling may arise. Hu et al. [9]
present a modelling approach, by ways of a nonlinear model, to assess bioequivalence
or PK similarity for parameters estimated in a serial sampling design. Wolfsegger
[10] presented three methods for calculation of a 1−α confidence interval for the ratio
of two AUC’s from zero to the last time point without assuming a specific nonlinear
model.
We will proceed by giving an overview of the ratio of AUC’s in serial sampling
designs and its estimation followed by a brief summary of seven methods to construct
confidence intervals considered in this simulation study. In Section 4 we will describe
the simulation study conducted in detail while Section 5 provides the simulation
results. We will conclude with an example and a brief discussion of the findings and
future directions.
2 Serial Sampling Design
Consider a study with two treatment groups, k, in which measurements are taken
at J time points, tj (1 ≤ j ≤ J), and at each time point blood is sampled from
nj analysis subjects. It is assumed that the time points are the same for the two
treatment groups and that each subject is only sampled once across all timepoints.
This design leads to independent random variables, both per time point as well
as between time points. Let Xijk be the measured drug concentration from the
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ith analysis subject at time tj receiving the treatment k. Let E[Xijk] = µjk and
V [Xijk] = σ
2
jk be the population mean and population variance at time point tj. The
general heteroscedastic model then is defined as
Xijk = µjk + ijk (1)
where the errors, ijk, are identical and independently distributed with continuous
distribution Gjk and the range of Xijk is effectively positive. The theoretical AUC




































i=1 Xijk represents the arith-
metic mean at time point tj in the k
th treatment group.



















Wolfsegger [10] shows that
√
n(∆ˆ −∆) is asymptotically normal distributed. A
similar approach can be used to estimate the ratio of AUCs from 0 to infinity by
replacing the presented formulas for the AUC with the respective formulas for the
AUC from 0 to infinity in [5]. An approximate 1−α confidence interval for the ratio
can be obtained by application of Fieller’s theorem [11] based on the asymptotic
normal distribution and corresponding standard errors.
3 Methods Compared
In this section we will give a brief overview of the seven different methods to con-
struct (approximate) 1−α confidence intervals that are considered in the simulation
study of Section 4. We will denote the parameter of interest by θ and a standard
estimator for it (e. g. maximum likelihood estimator) by θˆ. Further, in accordance
to Davison & Hinkley [12] and others, we will use the ‘star’ notation to indicate
bootstrap based estimators. Therefore, θˆ∗(b) is the bth bootstrap replication of the
estimator θˆ. The α-percentile of the set of bootstrap replicates {θˆ∗(b), b = 1, . . . , B}
will be denoted by θˆ∗α.
The simplest and probably most often used resampling method to construct con-
fidence intervals among practitioners is the percentile method [13, pp. 170-177]. This
method assumes that for an unknown monotone increasing transformation h(θ), a
statement of the type










An improvement upon the percentile method was introduced by Efron [14] in the
bias-corrected and accelerated percentile method, BCa. As before this method has
the assumption of the existence of an unknown monotone increasing transformation,
h(θ), for which the statement
h(θˆ)− h(θ) ∼ N(−z0σh(θ), σ2h(θ))
holds. z0 denotes a constant bias correction factor and the relationship σh(θ) =
1 − ah(θ) holds for some a, the skewness correction factor (also referred to as the











with zcorrα = z0 +
z0+zα
1−a(z0+zα) , Φ(x) the CDF of the standard normal distribution
and zα the corresponding α-percentile. While it is not necessary for both methods
described above to know the transformation h(.), they will fail if the transformation
to a normal distribution is not possible.
A different type of bootstrap intervals can be constructed based on pivotal quan-
tities. The hybrid method [15] is the most intuitive of these approaches. The idea
is to estimate the distribution of the pivot θˆ − θ by the bootstrap distribution con-
structed upon θˆ∗(b)− θˆ, the bootstrap equivalent of the pivot. The confidence limits
then can be found to be
[2θˆ − θˆ∗1−α
2
; 2θˆ − θˆ∗α
2
]. (9)
Although this method has a totally different justification than the percentile
method, it is easy to see the connection between both methods. The hybrid method,
however, in this note is particularly interesting since the next method, called the
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ratio method is based upon its idea.
For the ratio method introduced in [16], we consider a different pivot, θˆ
θ
, whose













as the confidence bounds. A very particular feature of this method is that it
should only be used if the values of the statistic are strictly positive, a feature clearly
prominent in the estimation of the AUC and ratio of two AUC’s. It does, however,
also imply that the propagated error, which arises by every further iteration, emerges
in an approximately multiplicative way. In other words, the method will work poorly
if the distribution to be estimated deviates strongly from the estimate. This, fur-
thermore, means that the sample sizes required tend to be large.
The assumptions of the bootstrap-t-interval [17] are less restrictive than those
of the hybrid method, allowing the pivot to be of a more general form θˆ−θ
σˆ
whose
distribution is to be estimated by the distribution of t∗ = θˆ
∗(b)−θˆ
σˆ∗ . The resulting
confidence interval then becomes
[θˆ − t∗1−α
2
σˆ; θˆ − t∗α
2
σˆ]. (11)
Notice that, in order to obtain good results for this type of interval, in addition
to the bootstrap statistic t∗ a separate estimator of the standard deviation, σˆ∗ (usu-
ally the jackknife estimator for σ) is needed. To obtain this estimator generally one
additional ‘layer’ of resampling is necessary, making this method often more compu-
tational intensive than the intervals presented before. Furthermore, this additional
bootstrap layer may lead to poor estimates in the case of small sample sizes per
time point which is frequently the case in non-clinical in-vivo studies. In this study,
instead of a resampled estimator for σ, we used the asymptotic standard deviation
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derived in [10] to avoid these problems.
The last two methods considered in the manuscript differ from the previous meth-
ods significantly as they are not resampling based methods. The asymptotic confi-
dence interval simply uses normal theory to obtain a z-type interval as
[θˆ + zα
2
σˆθˆ; θˆ + z1−α2 σˆθˆ].
This technique has the implicit assumption that some form of a limiting theory
holds for the statistic such that θˆ−θ
σˆθˆ
∼. N(0, 1). This approach will result in a sym-
metric confidence interval around the observed effect which is often inappropriate
in the case of ratios since the parameter space for ratios ranges from 0 to infinity.
The Fieller-type procedure, which is described in great detail in [10] for the ratio
of AUC’s, on the other hand uses a t-distribution to model the distribution of the
corresponding pivot. The degrees of freedom are approximated using Satterthwaite’s
method [18], yielding a complicated looking, but computationally straightforward,
confidence interval.
4 Simulations
The following one-compartmental model with first order absorption and elimination
after extravascular administration (e. g. oral, intramuscular, rectal, etc.) was used
for data generation
Xij = f (tj) + ij =
kaFD
V (ka − λ)
(
e−λtj − e−katj)+ ij (12)
with the parameterization λ = 0.0693, ka = 0.231, V = 10, F = 1 and the dose
D = 500. To eliminate the bias created by the linear trapezoidal rule to approx-
imate the integral, the true AUC for treatment k was defined as in Equation (2)




e−λtj − e−katj) specified at baseline and ten time points
(1h, 2h, 3h, 4h, 6h, 8h, 12h, 18h, 24h and 36h) post study drug administration.
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Both, model and time points, are taken from Gibaldi & Perrier, page 440 [19]. For
each subject only one observation is generated across all time points to reflect the
sparse sampling situation of the serial sampling design. As a result all generated
observations are independent of each other. Consequently missing data effectively
reduces the sample size at specific time points, but need no special consideration in
the estimation of the AUC’s in serial sampling designs as the presented procedures
allow for unequal sample sizes per time point.
Normal, log-normal and double exponential distributed errors were used for vari-
ous combinations of sample size (N=3, 5 and 10) and time point variabilities. Table
1 shows the three variability scenarios that were studied which are inspired by real
data. The coefficient of variations at later time points tend to increase which might
be due to the inaccuracy of an assay to determine the drug concentration in the
blood when dealing with values close to the limit of detection. 10000 simulation runs
(yielding an estimation error of 0.003 for nominal coverage of 90%) were carried out
for each parameter setting with preselected sample sizes. Within each simulation
run, N random samples were generated for each of the specified time points. 1000
bootstrap replications were used for bootstrap based confidence intervals.
Table 1: Coefficient of Variations (%) Used for Simulations
Time point
Scenario Baseline 1 to 18 hours 24 hours 36 hours
1 0% 20% 20% 20%
2 0% 40% 40% 40%
3 0% 40% 80% 80%
Empirical coverage estimates are reported for a nominal coverage probability of
1 − α = 0.90. Empirical lower and upper tail probabilities presented additionally
were defined as the probability that the true ratio is below/above the calculated
two-sided 90% confidence interval for the ratio. Empirical type I errors, γ, in the
sense of bioequivalency are reported under non-equivalence for a nominal coverage
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probability of 1− α = 0.90.
Empirical power and type I error estimates are presented using the conventional
limits of bioequivalence for ratio of averages ranging from 0.8 to 1.25. Expected val-
ues at different time points used to study ∆ = 0.799 and ∆ = 0.90 were determined
by varying parameters λ, ka, V , D and F accordingly.
All simulations were performed with R version 2.4.1 [20]. Empirical coverage,
power and type I error for the methods compared for a given scenario and sample
size per time point were calculated on basis of the same simulation runs.
4.1 Generation of Error Terms
Our starting point to model the uncertainty in the AUC will be normally distributed
errors, since some of the theoretical results are based upon this assumption [10].
Additionally, log-normal distributed errors will be evaluated as drug levels cannot be
negative, while the upper end is open which may lead to a non-symmetrical distri-
bution. The last distribution considered, a double exponential distribution, is used
to represent frequent extreme observations. For all distributions we use the param-
eterization in Casella & Berger, pages 623-625 [21].
The variation in the drug levels at a given time point has been fixed in terms of
the dimensionless coefficient of variation, cv = σ/µ, where µ is the mean drug level
at a given time point and σ the corresponding standard deviation. While the mean
level, µ, is given by the true AUC the challenge is to find the parameters of the un-
derlying distribution that yield a pre-specified coefficient of variation. For the normal
distribution, where the parameters of the distribution correspond to the moments
of interest, the solution is simple and given by data generated from a N (µ, µ2c2v)
-distribution.
To find the parameters for the other two distributions, however, is more difficult.
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Lets first consider the log-normal case for which we let α and β be the mean and
standard deviation of the underlying normal distribution, respectively. The mean of
the distribution then is exp (α + β2/2) and the coefficient of variation can be found
to be
√
exp (β2)− 1. To determine the proper values for α and β for given values of









which yields α = ln (µ) − 1
2
ln (1 + c2v) and β
2 = ln (1 + c2v). The data for this
model therefore can be obtained by generating data from a log-normal distribution
with the parameters from above.
Using the equivalent approach for the double exponential distribution parame-
terized by α and β gives the set of equations






which are solved by α = µ and β2 = 1
2
µ2c2v. Thus, we can generate the heavy
tailed distribution by using a double exponential distribution with the respective
parameters.
In the rare case that we generated a negative value using the normal and double
exponential distribution, we chose to simply replace the value by a newly generated
nonnegative observation. While we are aware that this will change the true underly-
ing structure of the model we found that the difference in µ and cv was negligible as
only a few observations had to be replaced. Further, this approach was applied for
both samples for which the ratio of AUC’s was calculated and additional simulation




Aside from the ‘clean’ data situations described before, we also study contaminated
data. The first set of contaminations is thought to describe either erroneous data due
to measurement errors or extreme drug-levels for a few subjects at some time points.
In our model we use the same normal and log-normal distributions as described in
Section 4.1 with cv = 0.2 but have 10% of the data generated come from the same
distribution with the mean shifted by 3 standard deviations. For the normal distri-
bution this yields a true cv of 0.254 while the coefficient of variation becomes 0.305
for log-normal data.
The second type of contamination studied is a change in the error distribution over
time. This is motivated by potentially different decomposition of the drug among
subjects. We will model this by having the initial error distribution be normal and
change it to double exponential for the last three time points. The coefficient of
variation will be 0.2 at all time points. Note that this approach is different to just
changing cv for the last 3 time points since this still has the coefficient of variation
fixed while increasing the number of extreme values.
5 Results
Tables 2 - 5 show some of the results of the simulation study for the ‘clean’ data for
the scenarios in Table 1. The omitted results are available from the authors upon
request. For all combinations of sample size, distribution and ∆, the empirical over-
all coverage and the empirical power/type-I-error is presented. Additionally left and
right tail coverages are included as they are important for one sided hypothesis such
as tests for non-inferiority. The power in this context is defined as the probability
that the confidence interval estimated is within 0.8 and 1.25, the conventional range
for bioequivalency.
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The bootstrap confidence intervals with the exception of the bootstrap-t-interval
show a clear pattern in terms of coverage for all parameter settings considered. For
a sample size of 3 per time point these intervals undercover severely, yielding only
an empirical coverage of approximately 0.8 while they approach nominal coverage as
sample size increase. The bootstrap-t-interval as well as the asymptotic and Fieller
type interval are superior in coverage than the other procedures investigated for all
sample sizes and scenarios studied. Empirical coverage of the asymptotic proce-
dure is slightly below the nominal coverage level for a sample size of 3 whereas the
bootstrap-t and Fieller approach yield nominal coverage. In addition, the asymptotic
interval indicates imbalance in tail probabilities. On average, the Fieller approach
is marginally more conservative in terms of coverage than the bootstrap-t approach
with double exponential errors and a sample size of 3 per time point. However, differ-
ences in power and type-I-error between the Fieller interval and bootstrap-t-interval
are small across all sample size and error distributions considered.
Another interesting point is that there appears to be no influence of the error
distribution on the coverage of the different types of confidence intervals while the
power clearly depends on the distributional shape and the values of the coefficient
of variation across time points.
A surprising result can be found for the hybrid intervals for which the empirical
coverage of the tails differ strongly such that the lower bound covers much better
and, in fact almost always, yields the desired coverage on the lower tail, while badly
undercovering on the upper tail. Interestingly the same behavior can not be found
for the related ratio method. While the poor coverage suggests a poor approximation
of the distribution of the pivot by the bootstrap distribution, the resulting intervals
appear to be more symmetric in probability.
In the simulation for equivalent true AUC’s (∆ = 1), presented in Tables 2 and
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5, the power quickly reaches one for a coefficient of variation of 0.2 and 0.4 as sample
size increases. An interesting side note here is that the double exponential errors
yield a higher power than the other two error distributions considered. This may be
due to the effectively smaller value of cv obtained by replacing negative values by a
new, positive, random error.
For the situation of different AUC’s that are still considered to be bioequivalent
(∆ = 0.9) hardly any difference in the performance of the intervals dependent on the
error distribution can be found once again. Only for the high variation scenario a
slight difference in power between the symmetric and the non-symmetric error dis-
tribution can be seen (Table 5). The magnitude of this difference is at most 7%. It
is notable, however, that the power of all intervals is markedly lower than for ∆ = 1
across all sample sizes with up to 40% reduced power for scenario 3.
The most encouraging results for all the methods considered can be found for
AUC’s that are not considered bioequivalent. Even when the true parameter is only
0.001 outside of the range of bioequivalency, all the confidence intervals reflect this
yielding only a type-I-error, γ, that is the probability to decide on equivalency when
you should not, of approximately 5%. Even more astonishing is that the value of γ
is stable across all choices of distribution, sample size and variations.
5.1 Contamination
We will now look at the performance of the intervals for contaminated data. In
terms of coverage the results mimic the pattern discussed for the ‘clean’ data. The
bootstrap-t-interval, asymptotic and Fieller interval are superior in coverage to the
other procedures investigated across all sample size and error distributions consid-
ered.
The power of the contaminated errors show the expected pattern as the power
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Table 2: Empirical Coverage and Power for ∆ = 1 Using a Nominal Coverage of 90% for
Scenario 1
Error distribution
Normal Log-normal Double exponential
N Method Coverage Power Coverage Power Coverage Power
3 Percentile 0.8063 (0.9048;0.9015) 0.9459 0.8013 (0.9012;0.9001) 0.9505 0.7986 (0.9004;0.8982) 0.9373
Hybrid 0.8072 (0.9240;0.8832) 0.9450 0.7948 (0.9165;0.8783) 0.9459 0.8109 (0.9259;0.8850) 0.9378
Ratio 0.8067 (0.9049;0.9018) 0.9490 0.7977 (0.8987;0.8990) 0.9492 0.8091 (0.9055;0.9036) 0.9436
BCa 0.8046 (0.9032;0.9014) 0.9464 0.8001 (0.9003;0.8998) 0.9493 0.7985 (0.9000;0.8985) 0.9338
Boot-t 0.9110 (0.9579;0.9531) 0.8438 0.9110 (0.9579;0.9531) 0.8388 0.9118 (0.9602;0.9516) 0.7951
Asymptotic 0.8835 (0.9514;0.9321) 0.8985 0.8796 (0.9474;0.9322) 0.9002 0.8857 (0.9543;0.9314) 0.8847
Fieller 0.9072 (0.9527;0.9545) 0.8699 0.9078 (0.9541;0.9537) 0.8718 0.9314 (0.9684;0.9630) 0.8245
5 Percentile 0.8513 (0.9259;0.9254) 0.9934 0.8483 (0.9247;0.9236) 0.9952 0.8415 (0.9219;0.9196) 0.9913
Hybrid 0.8526 (0.9397;0.9129) 0.9937 0.8443 (0.9374;0.9069) 0.9945 0.8524 (0.9428;0.9096) 0.9921
Ratio 0.8525 (0.9261;0.9264) 0.9935 0.8469 (0.9251;0.9218) 0.9944 0.8526 (0.9273;0.9253) 0.9926
BCa 0.8522 (0.9252;0.9270) 0.9930 0.8469 (0.9229;0.9240) 0.9948 0.8388 (0.9193;0.9195) 0.9898
Boot-t 0.9040 (0.9534;0.9506) 0.9871 0.8999 (0.9524;0.9475) 0.9878 0.8897 (0.9471;0.9426) 0.9746
Asymptotic 0.8925 (0.9526;0.9399) 0.9892 0.8899 (0.9531;0.9368) 0.9910 0.8907 (0.9533;0.9374) 0.9860
Fieller 0.9038 (0.9510;0.9528) 0.9873 0.9039 (0.9535;0.9504) 0.9896 0.9025 (0.9523;0.9502) 0.9840
10 Percentile 0.8790 (0.9426;0.9364) 1.0000 0.8698 (0.9364;0.9334) 1.0000 0.8765 (0.9415;0.9350) 0.9999
Hybrid 0.8763 (0.9520;0.9243) 1.0000 0.8687 (0.9448;0.9239) 1.0000 0.8803 (0.9536;0.9267) 0.9999
Ratio 0.8802 (0.9430;0.9372) 1.0000 0.8689 (0.9351;0.9338) 1.0000 0.8807 (0.9442;0.9365) 0.9999
BCa 0.8768 (0.9404;0.9364) 1.0000 0.8683 (0.9325;0.9358) 1.0000 0.8723 (0.9379;0.9344) 0.9999
Boot-t 0.9019 (0.9538;0.9481) 1.0000 0.8936 (0.9480;0.9456) 1.0000 0.8945 (0.9504;0.9441) 0.9999
Asymptotic 0.8985 (0.9560;0.9425) 1.0000 0.8882 (0.9496;0.9386) 1.0000 0.8988 (0.9567;0.9421) 0.9999
Fieller 0.9023 (0.9529;0.9494) 1.0000 0.8949 (0.9475;0.9474) 1.0000 0.9053 (0.9547;0.9506) 0.9999
Values in parentheses refer to left and right tail probabilities
Power is based on conventional limits for bioequivalency
N is sample size per time point
increases with sample size for ∆ = 1 and ∆ = 0.9 while the type-I-error is rather
stable at 5% for non-equivalent AUC’s. The biggest and most surprising difference
can be seen between the error distributions. The contaminated log-normal distribu-
tion (Table 6) has markedly better power for the values of the parameter that are
considered bioequivalent than the contaminated normal distribution (Table available
upon request). In fact the power of the contaminated log-normal distribution is up
to 25% higher than for normally distributed errors and is almost identical to the
power for the ‘clean’ normal errors. This result suggests that the power of the inter-
vals is not so much influenced by the skewness of the error distribution than by the
frequency of outliers. Keeping this in mind it is striking that the same feature was
not seen in the initial simulations using ‘clean’ errors. This further indicates that the
extreme tail needs to be very heavy in order to yield a reduction in power as seen here.
The results for changing error distribution once again show the familiar patterns
and the details therefore have been omitted, but are available upon request. The
coverage of the bootstrap based methods converges in sample size toward nominal
level for all these methods besides the bootstrap-t-interval whos coverage is on target
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Table 3: Empirical Coverage and Type I Error for ∆ = 0.799 Using a Nominal Coverage
of 90% for Scenario 1
Error distribution
Normal Log-normal Double exponential
N Method Coverage γ Coverage γ Coverage γ
3 Percentile 0.8046 (0.9028;0.9018) 0.0949 0.8047 (0.9020;0.9027) 0.0946 0.7984 (0.8985;0.8999) 0.0961
Hybrid 0.8082 (0.9235;0.8847) 0.1107 0.8036 (0.9194;0.8842) 0.1123 0.8090 (0.9222;0.8868) 0.1090
Ratio 0.8084 (0.9036;0.9048) 0.0921 0.8013 (0.9007;0.9006) 0.0965 0.8071 (0.9033;0.9038) 0.0931
BCa 0.8046 (0.9015;0.9031) 0.0930 0.8055 (0.9012;0.9043) 0.0923 0.7922 (0.8948;0.8974) 0.0985
Boot-t 0.9142 (0.9572;0.9570) 0.0414 0.9149 (0.9588;0.9561) 0.0422 0.9100 (0.9580;0.9520) 0.0453
Asymptotic 0.8853 (0.9505;0.9348) 0.0636 0.8821 (0.9496;0.9325) 0.0645 0.8826 (0.9512;0.9314) 0.0655
Fieller 0.9258 (0.9627;0.9631) 0.0357 0.9187 (0.9591;0.9596) 0.0384 0.9047 (0.9533;0.9514) 0.0466
5 Percentile 0.8462 (0.9246;0.9216) 0.0751 0.8451 (0.9246;0.9205) 0.0754 0.8429 (0.9197;0.9232) 0.0727
Hybrid 0.8481 (0.9407;0.9074) 0.0897 0.8439 (0.9378;0.9061) 0.0905 0.8512 (0.9392;0.9120) 0.0841
Ratio 0.8465 (0.9251;0.9214) 0.0761 0.8453 (0.9244;0.9209) 0.0761 0.8506 (0.9238;0.9268) 0.0703
BCa 0.8449 (0.9232;0.9217) 0.0753 0.8436 (0.9221;0.9215) 0.0757 0.8384 (0.9161;0.9223) 0.0751
Boot-t 0.8984 (0.9511;0.9473) 0.0503 0.8976 (0.9511;0.9465) 0.0506 0.8894 (0.9442;0.9452) 0.0524
Asymptotic 0.8861 (0.9529;0.9332) 0.0635 0.8853 (0.9517;0.9336) 0.0654 0.8892 (0.9509;0.9383) 0.0584
Fieller 0.9005 (0.9518;0.9487) 0.0492 0.8992 (0.9520;0.9472) 0.0500 0.9055 (0.9518;0.9537) 0.0436
10 Percentile 0.8760 (0.9396;0.9364) 0.0595 0.8763 (0.9401;0.9362) 0.0606 0.8762 (0.9371;0.9391) 0.0572
Hybrid 0.8751 (0.9488;0.9263) 0.0679 0.8749 (0.9489;0.9260) 0.0698 0.8815 (0.9501;0.9314) 0.0632
Ratio 0.8776 (0.9398;0.9378) 0.0581 0.8760 (0.9395;0.9365) 0.0587 0.8817 (0.9401;0.9416) 0.0552
BCa 0.8757 (0.9379;0.9378) 0.0584 0.8740 (0.9375;0.9365) 0.0594 0.8731 (0.9347;0.9384) 0.0578
Boot-t 0.8976 (0.9501;0.9475) 0.0483 0.8973 (0.9501;0.9472) 0.0484 0.8941 (0.9478;0.9463) 0.0511
Asymptotic 0.8953 (0.9531;0.9422) 0.0534 0.8937 (0.9531;0.9406) 0.0556 0.8977 (0.9537;0.9440) 0.0526
Fieller 0.8994 (0.9506;0.9488) 0.0486 0.9007 (0.9516;0.9491) 0.0471 0.9014 (0.9509;0.9505) 0.0464
Values in parentheses refer to left and right tail probabilities
N is sample size per time point
for all sample sizes. Additionally we see again the increasing power in sample size for
equivalent AUC’s while the type-I-error remains stable at about 5% if the areas are
in fact different. This suggests that the constructed intervals are rather insensitive
to distributional assumptions.
6 Example
To illustrate the seven methods the rats data [3] were used. We consider testing for
dose proportionality using the plasma concentrations based on doses of 30 mg/kg
and 100 mg/kg. The observed concentrations are scaled by the administered dose
and the corresponding AUC’s tested for equivalence. Figure 1 shows the two sets of
data while Table 7 displays the seven confidence intervals discussed based on 10000
bootstrap resamples.
The graph of the data shows that plasma concentrations at a dose of 30 mg/kg
are slightly lower at one and two hours and shows much higher variability at 4 hours
while otherwise matching the scaled results for a dose of 100 mg/kg well. All seven
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Table 4: Empirical Coverage for ∆ = 0.9 Using a Nominal Coverage of 90% for Scenario 3
Error distribution
Normal Log-normal Double exponential
N Method Coverage Coverage Coverage
3 Percentile 0.8100 (0.9052;0.9048) 0.7931 (0.8965;0.8966) 0.7998 (0.9002;0.8996)
Hybrid 0.8180 (0.9463;0.8717) 0.7894 (0.9356;0.8538) 0.8049 (0.9398;0.8651)
Ratio 0.8201 (0.9100;0.9101) 0.7835 (0.8911;0.8924) 0.8039 (0.9024;0.9015)
BCa 0.8103 (0.9035;0.9068) 0.7922 (0.8939;0.8983) 0.7970 (0.8968;0.9002)
Boot-t 0.9165 (0.9634;0.9531) 0.9091 (0.9617;0.9474) 0.9077 (0.9582;0.9495)
Asymptotic 0.8921 (0.9646;0.9275) 0.8743 (0.9579;0.9164) 0.8834 (0.9591;0.9243)
Fieller 0.9220 (0.9634;0.9586) 0.9098 (0.9572;0.9526) 0.9240 (0.9644;0.9596)
5 Percentile 0.8522 (0.9265;0.9257) 0.8454 (0.9238;0.9216) 0.8446 (0.9207;0.9239)
Hybrid 0.8587 (0.9615;0.8972) 0.8378 (0.9520;0.8858) 0.8497 (0.9522;0.8975)
Ratio 0.8588 (0.9301;0.9287) 0.8412 (0.9221;0.9191) 0.8498 (0.9225;0.9273)
BCa 0.8519 (0.9241;0.9278) 0.8428 (0.9189;0.9239) 0.8403 (0.9151;0.9252)
Boot-t 0.9059 (0.9556;0.9503) 0.8947 (0.9508;0.9439) 0.8951 (0.9480;0.9471)
Asymptotic 0.8975 (0.9652;0.9323) 0.8825 (0.9569;0.9256) 0.8895 (0.9572;0.9323)
Fieller 0.9135 (0.9565;0.9570) 0.9129 (0.9582;0.9547) 0.9062 (0.9511;0.9551)
10 Percentile 0.8846 (0.9435;0.9411) 0.8647 (0.9328;0.9319) 0.8740 (0.9359;0.9381)
Hybrid 0.8848 (0.9649;0.9199) 0.8646 (0.9555;0.9091) 0.8778 (0.9577;0.9201)
Ratio 0.8868 (0.9447;0.9421) 0.8635 (0.9324;0.9311) 0.8743 (0.9361;0.9382)
BCa 0.8830 (0.9397;0.9433) 0.8611 (0.9274;0.9337) 0.8709 (0.9306;0.9403)
Boot-t 0.9072 (0.9559;0.9513) 0.8878 (0.9454;0.9424) 0.8923 (0.9461;0.9462)
Asymptotic 0.9055 (0.9641;0.9414) 0.8839 (0.9544;0.9295) 0.8950 (0.9561;0.9389)
Fieller 0.9068 (0.9552;0.9516) 0.8968 (0.9489;0.9479) 0.8993 (0.9486;0.9507)
Values in parentheses refer to left and right tail probabilities
N is sample size per time point
lower bounds of the two-sided 90% confidence intervals fall below the conventional
margins of bioequivalence for ratios of averages ranging from 0.8 to 1.25, indicating
that dose proportionality can not be established. As expected the bootstrap-t and
the Fieller interval are widest, which is reflected in the higher coverage in the simu-
lation studies above.
7 Discussion
In this note the performance of seven different types of confidence intervals for the
ratio of two area under the concentration versus time curves in a serial sampling de-
sign, where the otherwise comonly used two-stage approach is not applicable due to
sparsity, are evaluated. For all combinations of variation, sample size and distribu-
tion the asymptotic, Fieller and bootstrap-t-interval are clearly superior to the other
approaches considered. Among these three intervals only small difference in coverage
or power/type-I-error can be seen which is particularly surprising for the asymptotic
interval for contaminated data as it implies that the asymptotic normality shown in
[10] is reached quickly. This result strengthened the argument to use the asymptotic
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Table 5: Power and Type I error for different ∆ Using a Nominal Coverage of 90% for
Scenario 3
Error distribution
Normal Log-normal Double exponential
∆ = 1 ∆ = 0.9 ∆ = 0.799 ∆ = 1 ∆ = 0.9 ∆ = 0.799 ∆ = 1 ∆ = 0.9 ∆ = 0.799
N Method Power Power γ Power Power γ Power Power γ
3 Percentile 0.2447 0.1823 0.0644 0.2249 0.1685 0.0680 0.3418 0.2554 0.0819
Hybrid 0.2164 0.1845 0.0753 0.1875 0.1700 0.0776 0.3153 0.2667 0.1010
Ratio 0.2489 0.1852 0.0632 0.2232 0.1662 0.0702 0.3441 0.2520 0.0803
BCa 0.2465 0.1789 0.0643 0.2227 0.1656 0.0669 0.3376 0.2514 0.0818
Boot-t 0.0506 0.0366 0.0118 0.0469 0.0308 0.0143 0.1051 0.0769 0.0212
Asymptotic 0.0879 0.0665 0.0240 0.0771 0.0634 0.0268 0.1651 0.1333 0.0393
Fieller 0.0387 0.0298 0.0089 0.0492 0.0363 0.0159 0.0890 0.0645 0.0166
5 Percentile 0.4805 0.3170 0.0696 0.4306 0.2832 0.0702 0.5714 0.3715 0.0730
Hybrid 0.4525 0.3589 0.0923 0.3903 0.3133 0.0952 0.5526 0.4157 0.0974
Ratio 0.4898 0.3184 0.0665 0.4284 0.2835 0.0729 0.5747 0.3693 0.0703
BCa 0.4756 0.3106 0.0668 0.4261 0.2788 0.0679 0.5672 0.3618 0.0714
Boot-t 0.3367 0.2138 0.0413 0.2590 0.1638 0.0407 0.4162 0.2644 0.0472
Asymptotic 0.3603 0.2569 0.0559 0.3021 0.2135 0.0575 0.4634 0.3153 0.0626
Fieller 0.3119 0.1883 0.0341 0.2366 0.1453 0.0335 0.4231 0.2569 0.0414
10 Percentile 0.8550 0.5196 0.0574 0.7809 0.4685 0.0657 0.8973 0.5656 0.0605
Hybrid 0.8428 0.5825 0.0767 0.7656 0.5307 0.0878 0.8917 0.6234 0.0764
Ratio 0.8562 0.5225 0.0561 0.7798 0.4667 0.0663 0.8994 0.5661 0.0596
BCa 0.8497 0.5088 0.0551 0.7727 0.4578 0.0638 0.8945 0.5533 0.0580
Boot-t 0.8239 0.4854 0.0470 0.7233 0.4182 0.0551 0.8687 0.5255 0.0512
Asymptotic 0.8262 0.5226 0.0565 0.7431 0.4675 0.0686 0.8780 0.5647 0.0590
Fieller 0.8215 0.4823 0.0464 0.7349 0.4167 0.0501 0.8742 0.5219 0.0475
Power is based on conventional limits for bioequivalency
N is sample size per time point
standard deviation as an estimator for σ for the bootstrap-t and asymptotic intervals.
We recommend the use of the Fieller interval if the number of time points is moder-
ate to large since it does not rely on heavy computation like the bootstrap-t-interval
and it does not give symmetric confidence intervals as the asymptotic approach.
For a small number of time points where computation time is not an issue, the
bootstrap-t-interval should be used since it has fewer underlying assumptions and
yields almost identical results. The Fieller, asymptotic and bootstrap-t-interval pre-
sented in this paper will be implemented in the R-package PK [22] in the near future.
In vast contrast to prior expectation, the ratio method specifically designed for
problems of this type, showed poor coverage for small sample sizes and was ultimately
indistinguishable from the related hybrid interval in terms of overall coverage. A big
difference between these two, however, was to be found when looking at the tail-
behavior. The ratio method lead to more balanced tail coverages while the hybrid
method severely undercovered on the upper bound. This insight suggests that it
might be possible to refine the ratio method further by including a small sample bias
correction.
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Table 6: Empirical Coverage and Power for a contaminated log-normal distribution using
a Nominal Coverage of 90% for varying delta
Delta
1 0.9 0.799
N Method Coverage Power Coverage Power Coverage γ
3 Percentile 0.7911 (0.8933;0.8978) 0.9516 0.7916 (0.8941;0.8975) 0.6753 0.7915 (0.8949;0.8966) 0.1028
Hybrid 0.7925 (0.9117;0.8808) 0.9487 0.7930 (0.9125;0.8805) 0.7152 0.7927 (0.9135;0.8792) 0.1202
Ratio 0.7888 (0.8935;0.8953) 0.9510 0.7888 (0.8940;0.8948) 0.6729 0.7890 (0.8954;0.8936) 0.1059
BCa 0.7922 (0.8931;0.8991) 0.9518 0.7916 (0.8933;0.8983) 0.6715 0.7921 (0.8944;0.8977) 0.1021
Boot-t 0.9066 (0.9524;0.9542) 0.8406 0.9063 (0.9525;0.9538) 0.5040 0.9060 (0.9528;0.9532) 0.0465
Asymptotic 0.8725 (0.9442;0.9283) 0.8992 0.8724 (0.9446;0.9278) 0.5970 0.8720 (0.9448;0.9272) 0.0728
Fieller 0.8951 (0.9454;0.9497) 0.8842 0.8947 (0.9458;0.9489) 0.5290 0.8948 (0.9464;0.9484) 0.0513
5 Percentile 0.8430 (0.9192;0.9238) 0.9945 0.8429 (0.9200;0.9229) 0.7935 0.8428 (0.9210;0.9218) 0.0779
Hybrid 0.8415 (0.9347;0.9068) 0.9938 0.8412 (0.9353;0.9059) 0.8217 0.8412 (0.9364;0.9048) 0.0950
Ratio 0.8415 (0.9192;0.9223) 0.9945 0.8415 (0.9201;0.9214) 0.7922 0.8412 (0.9208;0.9204) 0.0791
BCa 0.8415 (0.9163;0.9252) 0.9940 0.8410 (0.9172;0.9238) 0.7892 0.8398 (0.9179;0.9219) 0.0777
Boot-t 0.8955 (0.9485;0.9470) 0.9862 0.8954 (0.9489;0.9465) 0.7217 0.8957 (0.9497;0.9460) 0.0539
Asymptotic 0.8851 (0.9481;0.9370) 0.9909 0.8852 (0.9486;0.9366) 0.7637 0.8854 (0.9495;0.9359) 0.0639
Fieller 0.8957 (0.9470;0.9487) 0.9890 0.8953 (0.9475;0.9478) 0.7280 0.8952 (0.9478;0.9474) 0.0525
10 Percentile 0.8830 (0.9414;0.9416) 1.0000 0.8830 (0.9424;0.9406) 0.9558 0.8832 (0.9436;0.9396) 0.0599
Hybrid 0.8825 (0.9503;0.9322) 1.0000 0.8826 (0.9510;0.9316) 0.9653 0.8819 (0.9518;0.9301) 0.0693
Ratio 0.8814 (0.9409;0.9405) 1.0000 0.8817 (0.9419;0.9398) 0.9569 0.8817 (0.9430;0.9387) 0.0609
BCa 0.8831 (0.9394;0.9437) 1.0000 0.8830 (0.9403;0.9427) 0.9527 0.8824 (0.9412;0.9412) 0.0584
Boot-t 0.9046 (0.9530;0.9516) 1.0000 0.9043 (0.9535;0.9508) 0.9419 0.9041 (0.9542;0.9499) 0.0499
Asymptotic 0.9011 (0.9558;0.9453) 1.0000 0.9009 (0.9568;0.9441) 0.9525 0.9011 (0.9576;0.9435) 0.0563
Fieller 0.9058 (0.9544;0.9514) 1.0000 0.9061 (0.9554;0.9507) 0.9440 0.9058 (0.9561;0.9497) 0.0500
Values in parentheses refer to left and right tail probabilities
Power is based on conventional limits for bioequivalency
N is sample size per time point
Table 7: Two-sided 90% confidence intervals for the ratio of AUCs of dose scaled plasma
concentrations of CPI 975 in rats








The most encouraging finding in this note is the great distinction between bioe-
quivalent and non-equivalent results for all intervals. While the intervals show good
power to assess bioequivalence when it is present (∆ = 1 and ∆ = 0.9), the type-I-
error drops to about 5% as soon as the true ratio is less than 0.8.
A natural extension of the work presented here is the use of batch designs. In
batch designs each analysis subject is sampled at more than one time point but not
at all time points. While a variety of authors such as Holder et al. [23] and Yeh
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[24] have proposed estimators for the AUC for this sampling design, its theoretical
properties are not yet well established. Furthermore, tests for bioequivalence have
to be developed and evaluated in this context.
Another point of interest regards observations that fall below the detection limit.
Common practice in this situation is to either set those values to half the detection
limit or zero. Setting all values below the detection limit to zero may be sufficient
for calculation of AUC’s but is not an option for other PK parameters as for example
when estimating terminal elimination rate where values of zero cannot be used. A
different approach to the ad-hoc methods mentioned before is to model non-detected
data as censored data. Lambert et al. [25] suggest a method in the context of envi-
ronmental data that should be explored further for medical data in general and the
estimation of pharmacokinetic parameters in particular.
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